https://scholars.lib.ntu.edu.tw/handle/123456789/640066
標題: | Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection | 作者: | Janssen, Harry L Lim, Young-Suk Kim, Hyung Joon Sowah, Leonard Tseng, Cheng-Hao Coffin, Carla S Elkhashab, Magdy Ahn, Sang Hoon Nguyen, Anh-Hoa Chen, Diana Wallin, Jeffrey J Fletcher, Simon P McDonald, Circe Yang, Jenny C Gaggar, Anuj Brainard, Diana M Fung, Scott Kim, Yoon Jun JIA-HORNG KAO Chuang, Wan-Long Brooks, Anna E Dunbar, P Rod |
關鍵字: | HBV cure; Hepatitis B virus; immunotherapy; oral antiviral; small molecule; toll-like receptor; viremic | 公開日期: | 二月-2024 | 卷: | 6 | 期: | 2 | 來源出版物: | JHEP reports : innovation in hepatology | 摘要: | Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and antiviral activity of selgantolimod (a Toll-like receptor 8 agonist [TLR8]) with tenofovir alafenamide (TAF). |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/640066 | ISSN: | 25895559 | DOI: | 10.1016/j.jhepr.2023.100975 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。